Treatment of active refractory rheumatoid arthritis with humanized monoclonal antibody campath‐1h administered by daily subcutaneous injection

Arthritis & Rheumatism

Volumn 38, Issue 9, 1995, Pages 1187-1193

  Matteson, Eric L ^a   Yocum, David E ^b   St Clair, E William ^c   Achkar, Antonio A ^a,f   Thakor, Michael S ^b   Jacobs, Mary R ^d   Hays, Anita E ^e   Heitman, Catherine K ^e   Johnston, Jeffrey M ^e  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e Burroughs Wellcome Co   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB;

ADULT; AGED; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ACTIVITY; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERANCE; FEMALE; FEVER; HUMAN; HYPOTENSION; INFECTION RISK; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, NEOPLASM; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOPROTEINS; HUMANS; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0029143898     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780380903     Document Type: Article

References (30)

1. Immunopathogenesis of rheumatoid arthritis
2. Predominantly T‐cell infiltrate in rheumatoid synovial membranes
3. Rheumatoid arthritis: pathophysiology and implications for therapy
4. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis (editorial)
5. Treatment of intractable rheumatoid arthritis with total lymphoid irradiation
6. Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis
7. Lymphocyte involvement in rheumatoid arthritis: studies during thoracic duct drainage
8. Cyclosporin A in severe, treatmentrefractory rheumatoid arthritis: a randomized study
9. Treatment of rheumatoid arthritis with an anti‐CD4 monoclonal antibody
10. Use of a chimeric monoclonal anti‐CD4 antibody in patients with refractory rheumatoid arthritis
11. Effects of administration of an anti‐CD5 plus immunoconjugate in rheumatoid arthritis: results of two phase II studies
12. Response to monoclonal CD7 antibody in rheumatoid arthritis
13. Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T‐cells in rheumatoid arthritis
14. Treatment of rheumatoid arthritis with single dose or weekly pulses of chimeric anti‐CD4 monoclonal antibody
15. Treatment of rheumatoid arthritis with anti CD4 monoclonal antibody: open study of 25 patients with the B‐F5 clone
16. The Campath‐1 antigen (Cdw52)
17. Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes complement
18. Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH‐1 monoclonal antibodies
19. In vivo use of Campath‐1G to prevent graft‐versus‐host disease and graft rejection after bone marrow transplantation
20. Campath‐1M: prophylactic use after kidney transplantation; a randomized controlled clinical trial
21. Reshaping human antibodies for therapy
22. Remission induction in non‐Hodgkin's lymphoma with reshaped human monoclonal antibody CAMPATH‐1H
23. Long‐term remission of intractable systemic vasculitis with monoclonal antibody therapy
24. Humanised monoclonal antibody therapy for rheumatoid arthritis
25. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
26. Analysis of improvement in individual rheumatoid arthritis patients treated with disease‐modifying antirheumatic drugs, based on the findings in patients treated with placebo
27. A simple method for measuring patient anti‐globulin responses against isotypic or idiotypic determinants
28. Treatment of rheumatoid arthritis with humanized monoclonal antibody, CAMPATH‐1H
29. Clinical status of rheumatoid arthritis patients 18 months after treatment with chimeric anti‐CD4 antibody
30. Multicenter trial of an anti‐CD5 immunoconjugate in rheumatoid arthritis